Date: 2015-03-27
Type of information: Nomination
Compound:
Company: Atara Biotherapeutics (USA - CA)
Therapeutic area: Cancer - Oncology - Kidney diseases - Renal diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 27, 2015, Atara Biotherapeutics, a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases, announced that Eric Dobmeier has joined its Board of Directors.Mr. Dobmeier is currently the Chief Operating Officer of Seattle Genetics, Inc., a biotechnology company. Mr. Dobmeier joined Seattle Genetics in March 2002 and has served in positions of increasing responsibility since then, most recently as Chief Business Officer from May 2007 to June 2011. Prior to joining Seattle Genetics, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier also serves as a director of Stemline Therapeutics, Inc., a public biotechnology company. Mr. Dobmeier received a J.D. from the University of California, Berkeley School of Law and an A.B. in History from Princeton University.
Financial terms:
Latest news:
